SCHEMBL7245463

SCHEMBL7245463

c1ccc2c(c1)oc1cc(CNc3ccc4oc5ccccc5c4c3)ccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP2D6 P10635 1/20 0.47
KMT2A Q03164 7/20 0.46
MEN1 O00255 6/20 0.46
SMN1; SMN2 Q16637 6/20 0.46
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 3/20 0.46
MAPT P10636 3/20 0.46
HPGD P15428 3/20 0.46
LMNA P02545 3/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NPC1 O15118 6/20 0.45
RAB9A P51151 6/20 0.45
TP53 P04637 1/20 0.45
POLB P06746 1/20 0.45
TSHR P16473 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7246584 0.94 CYP1A2 (0.53) MAOBCYP1A2CYP2C19CYP2D6KMT2A
SCHEMBL6482295 0.88 HPGD (0.54) MAOBCYP1A2CYP2C19CYP2D6KMT2A
SCHEMBL6482150 0.86 CYP1A2 (0.49) MAOBCYP1A2CYP2C19CYP2D6KMT2A
SCHEMBL6493823 0.85 EGFR (0.50) MAOBCYP1A2CYP2C19CYP2D6KMT2A
SCHEMBL6493319 0.85 HTT (0.53) MAOBCYP1A2CYP2C19CYP2D6KMT2A
SCHEMBL6484790 0.84 MAPT (0.57) KMT2AMEN1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL6480507 0.83 HIF1A (0.51) MAOBCYP1A2CYP2C19CYP2D6KMT2A
SCHEMBL6497189 0.83 IDO1 (0.54) MAOBSMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL6490356 0.83 HPGD (0.52) MAOBALDH1A1KDM4EMAPTHPGD
SCHEMBL6483310 0.83 MAOB (0.46) MAOBCYP1A2CYP2C19CYP2D6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 MAOB 428/4885CYP1A2 649/4885CYP2C19 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.